David Saxon, an analyst from Needham, reiterated the Buy rating on RxSight. The associated price target was raised to $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Saxon has given his Buy rating due to a combination of factors including RxSight’s impressive third-quarter revenue performance, which exceeded market expectations. The company’s management has also raised the midpoint of its financial guidance, indicating confidence in future growth.
Additionally, RxSight is adopting a more strategic approach to its LDD placements, focusing on increasing LAL volumes through various engagement initiatives. The company is also targeting consistent quarterly growth in 2026, and its gross margin is expected to remain robust, staying in the high-70% range. These positive indicators collectively support the Buy rating.